Clinical Trial Update: A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dalotuzumab in combination with erlotinib for non-small cell lung cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dalotuzumab (dalotuzumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-small-cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2016-12-28